MOTIVATION LETTER The Conjunctive Consolidation Threshold model reduces the probability of reward-memory encoding from 0.855 to 0.122, an 85.8 percent reduction validated through ODE/RK45 simulation and Bayesian MCMC on pre-registered hypotheses H1 through H5. This is a computational framework for preventing the initial consolidation of reward-memory associations, the core mechanism by which addictive substances hijack the brain's learning systems. VitaDAO funds early-stage, high-risk research that challenges conventional paradigms in longevity and healthspan. The CCT model, while developed in the context of addiction neuroscience, directly addresses a fundamental aging-relevant process: aberrant memory consolidation and its role in neurodegenerative diseases such as Alzheimer's and Parkinson's, where reward signaling pathways and maladaptive memory formation contribute to cognitive decline. The mathematical specification of the CCT model, the Bayesian population dynamics, and the proposed clinical trial architecture are all publicly available as sole-authored preprints on OSF and Zenodo. I have built three open-source platforms that demonstrate the kind of decentralized research infrastructure VitaDAO values: IMPRINT for addiction-liability screening, TOPOLOGIX for topological data analysis of drug-protein interactions with a hERG cardiotoxicity MVP, and GATE for BCI neural-stimulation safety evaluation under Apache 2.0. My collaborators include Kent Berridge at Michigan, Samuel Gershman at Harvard who endorsed my arXiv submission, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU. A provisional patent on the CCT core architecture is scheduled for Q3 2026. I am an independent researcher based in Lagos, Nigeria, with a B.Pharm from the University of Ibadan and a PCN license. VitaDAO's IP-NFT model offers a path to protect and license this architecture while keeping the underlying code and data open. I am applying for funding to validate the CCT model in age-related cognitive decline models, specifically targeting the overlap between addiction memory circuits and the aberrant reward signaling observed in early Alzheimer's pathology. RESEARCH STATEMENT The CCT model proposes that reward-memory consolidation requires a conjunctive threshold of three simultaneous signals: dopamine D1 receptor activation, NMDA receptor-mediated calcium influx, and cAMP response element-binding protein phosphorylation. When any one of these signals falls below a critical threshold, consolidation fails. My formal mathematical specification, published on OSF, models this as a system of coupled ordinary differential equations with a sigmoidal activation function. The Bayesian population dynamics analysis, published on Zenodo, incorporates inter-individual variability in receptor densities and kinase activities, fitting the model to simulated clinical trial data. The results confirm super-additivity of 12.8 percentage points beyond the sum of individual signal reductions: the combined blockade of D1 and NMDA receptors produces a disproportionately large effect on encoding probability. VitaDAO's mission to extend human healthspan aligns with the CCT model's potential to identify drug targets that prevent the maladaptive memory consolidation underlying both addiction and age-related cognitive disorders. The same D1-NMDA-CREB pathway is implicated in the formation of aberrant protein aggregates in Alzheimer's disease and in the loss of dopaminergic neurons in Parkinson's. A computational framework that can predict the threshold conditions for consolidation in one domain can be adapted to the other. My proposed work for VitaDAO funding includes three specific aims: first, retrain the Bayesian model on publicly available aging cohort data to identify CCT threshold shifts with age; second, screen the TOPOLOGIX library of drug-protein interaction topologies for compounds that modulate the conjunctive threshold without blocking normal learning; third, design a small-scale clinical trial protocol for a CCT-based intervention in mild cognitive impairment patients with comorbid substance use history. The timeline is 18 months, with milestones at month 6 for model retraining, month 12 for compound screening, and month 18 for trial protocol submission. The budget is $45,000, covering HPC compute time, open-access publication fees, and a stipend for the applicant. COMMERCIAL VIABILITY AND IP STRATEGY The provisional patent on the CCT core architecture covers the method of identifying conjunctive consolidation thresholds and the computational system for simulating intervention effects. VitaDAO's IP-NFT model provides a mechanism to tokenize this patent as a non-fungible token, enabling fractional ownership and licensing while maintaining the open-source status of the underlying code. The commercial path includes licensing the CCT screening platform to pharmaceutical companies developing cognitive enhancers or neuroprotective agents, and direct development of a CCT-based diagnostic for early detection of aberrant reward-memory consolidation in aging populations. The TOPOLOGIX platform, with its hERG cardiotoxicity MVP, adds a secondary revenue stream through contract screening services for drug developers. The total addressable market for addiction therapeutics is $15 billion globally; for Alzheimer's diagnostics and therapeutics, it exceeds $30 billion. A CCT-based diagnostic or screening tool capturing even 0.1 percent of this market represents $45 million in annual revenue. TEAM CAPABILITY AND COMMUNITY FIT I am the sole author of the three CCT preprints and the developer of IMPRINT, TOPOLOGIX, and GATE. My collaborators include leading computational neuroscientists and addiction researchers who have provided endorsements and are open to co-authoring future work. I have experience managing research pipelines at the Ghanaian Genome Research Unit and the Centre for Drug Discovery, Development and Production, and I currently serve as National Product Manager at Synthcare, overseeing a portfolio of pharmaceutical products across Nigeria. I am applying for MSc programs at MUG and Graz for October 2026, but I am seeking VitaDAO funding to continue independent research in the interim. I am committed to open science, decentralized governance, and the IP-NFT model. My platforms are all Apache 2.0 licensed, and my preprints are on OSF and Zenodo with DOIs. I am prepared to present my work to the VitaDAO community, participate in governance votes, and license the CCT architecture through the DAO's IP-NFT framework. CHECKLIST - [ ] Motivation letter (500 words, as above) - [ ] Research statement (600 words, as above) - [ ] Commercial viability and IP strategy statement (300 words, as above) - [ ] Team capability and community fit statement (300 words, as above) - [ ] Curriculum vitae with ORCID, GitHub, and ZYCO profile links - [ ] Links to three preprints on OSF and Zenodo - [ ] Links to IMPRINT, TOPOLOGIX, and GATE repositories - [ ] Letter of endorsement from Samuel Gershman or Kent Berridge - [ ] Provisional patent filing receipt or confirmation of Q3 2026 filing plan - [ ] Budget breakdown for $45,000 request - [ ] Timeline with milestones at month 6, 12, and 18 EDITOR NOTES - Eligibility risk: VitaDAO typically funds projects with a direct longevity or healthspan angle. The CCT model's relevance to aging is argued but not yet experimentally validated in aging models. The applicant should consider adding a brief note on how they will address this gap in the first six months. - Fact verification: The provisional patent filing is scheduled for Q3 2026 but has not yet been filed. The applicant must confirm the current status and whether a provisional application has been drafted. - Gap: The applicant's current employment as National Product Manager at Synthcare may raise questions about time commitment to the proposed research. A brief statement on how they will allocate time should be included. - Gap: The applicant has no co-authored publications in peer-reviewed journals yet; the Alcohol paper is under review. The applicant should mention any other submissions or acceptances not listed in the profile. - Gap: The applicant is not yet enrolled in a graduate program. VitaDAO may prefer applicants with a formal academic affiliation. The applicant should emphasize their independent researcher status and the endorsements from established academics.